FindTrial
Sign In

Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis

Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222005
Enrollment
2000
Registered
2013-01-23
Start date
2013-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : iguratimod (Careram) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with rheumatoid arthritis All patients who take iguratimod

Exclusion criteria

Exclusion criteria: Pregnant women or women suspected of being pregnant Patients with a serious liver disorder Patients with peptic ulcer Patients with known hypersensitivity to iguratimod or any of its excipients

Design outcomes

Primary

MeasureTime frame
Efficacy DAS28—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026